Literature DB >> 25592727

Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice?

Danny Bega1, Paulina Gonzalez-Latapi, Cindy Zadikoff, William Spies, Tanya Simuni.   

Abstract

OBJECTIVE: Analyze indications for ordering DAT-SPECT scans and the clinical impact of scan results on patients evaluated in a movement disorders practice.
BACKGROUND: DAT-SPECT is FDA approved to evaluate cases of suspected presynaptic dopaminergic deficiency. Little data is available on clinical use and impact of these scans among movement disorders neurologists.
METHODS: DAT-SPECT scans ordered at the Northwestern University Parkinson's disease (PD) and movement disorders center from 2011-2013 were reviewed. Clinic notes were reviewed for information regarding the indication for ordering each scan, and to assess for any changes in clinical impression or management choices that followed the scan.
RESULTS: 83 scans were ordered by four specialists. Scans were commonly ordered to differentiate PD from Essential Tremor (21.7%, n = 18) or from drug-induced parkinsonism (21.7%, n = 18). In 59% (n = 49) of cases, a change in clinical diagnosis or medication regimen occurred within one visit after the scan. The strongest impact was seen for the indication of ET vs. PD in which 72.2% (n = 13) had a change in diagnosis, management, or both.
CONCLUSIONS: Diagnostic uncertainty in cases of parkinsonism exists even in a tertiary referral center. DAT-SPECT has significant impact on clinical diagnosis and management even in the hands of movement disorders specialists.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25592727     DOI: 10.1159/000370116

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  8 in total

Review 1.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

2.  Analysis of the Effect of Dopamine Transporter Scan on the Diagnosis and Management in a Tertiary Neurology Center.

Authors:  Shakya Bhattacharjee; Vijayashankar Paramanandam; Atrayee Bhattacharya
Journal:  Neurohospitalist       Date:  2019-02-14

Review 3.  Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis.

Authors:  Danny Bega; Phillip H Kuo; Anastasia Chalkidou; Mariusz T Grzeda; Thomas Macmillan; Christine Brand; Zulfiqar H Sheikh; Angelo Antonini
Journal:  NPJ Parkinsons Dis       Date:  2021-05-24

4.  Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease.

Authors:  Jonathan R Isaacson; Salima Brillman; Nisha Chhabria; Stuart H Isaacson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 5.  Insights into Pathophysiology from Medication-induced Tremor.

Authors:  John C Morgan; Julie A Kurek; Jennie L Davis; Kapil D Sethi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-11-22

6.  Interpreting 123I-ioflupane dopamine transporter scans using hybrid scores.

Authors:  Kenneth J Nichols; Brandon Chen; Maria B Tomas; Christopher J Palestro
Journal:  Eur J Hybrid Imaging       Date:  2018-05-21

Review 7.  Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.

Authors:  Sharadha Wisidagama; Abiram Selladurai; Peter Wu; Marco Isetta; Jordi Serra-Mestres
Journal:  Medicines (Basel)       Date:  2021-05-26

8.  Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging.

Authors:  Matthew F Covington; Scott Sherman; Denise Lewis; Hong Lei; Elizabeth Krupinski; Phillip H Kuo
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.